Aclaris ATI-052 Phase 1a shows favorable safety, 26-day half-life, near-complete target inhibition at low doses

Aclaris Therapeutics, Inc.

ATI-052 well tolerated up to 720 mg; no serious AEs, no discontinuations, mild injection site redness.
PK profile shows at least 26-day effective half-life with dose-proportional Cmax and AUC.
At 30 mg, robust concentration-dependent inhibition of IL-4 and TSLP stimulated CCL17/TARC.
Data supports potential for up to every-3-month dosing; Phase 1b in AD and asthma to start Q1 2026.
Phase 2b in atopic dermatitis planned for H2 2026; top-line data from Phase 1b expected H2 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.